news

  • 28 March 2018
    InDex Pharmaceuticals gets new patent in Japan

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the Japan Patent Office. The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.

    The divisional patent, entitled Method for prevention of colectomy (patent application number 2016218270), will provide an exclusivity period until November 2032, with the possibility of up to 5 years term extension after market approval.

    The company has received a notice of allowance from the Japan Patent Office. A corresponding patent was granted in the US in October 2017, and corresponding patent applications have been or will be filed in Europe and Canada and will be diligently prosecuted to grant.